Form 4: Lucid Diagnostics Director Receives Stock Options

Lucid Diagnostics Director John R. Palumbo was granted 215,000 employee stock options with an exercise price of $1.03, vesting over approximately two years.

Summary

• John R. Palumbo, a Director of Lucid Diagnostics Inc. (LUCD), was granted 215,000 employee stock options.
• The options have an exercise price of $1.03 per share.
• The transaction date for the grant was October 6, 2025.
• The options were granted under the issuer's Amended and Restated 2018 Long-Term Incentive Equity Plan.
• One-third of the options will vest on June 30, 2026.
• The remaining balance will vest in eight equal quarterly installments, commencing September 30, 2026, and concluding on June 30, 2028.
• The options expire on October 6, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management incentives with shareholder interests, which is generally viewed as a positive. However, it does not represent a significant new development or financial performance indicator for the company.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options were granted under an established long-term incentive plan, indicating a structured approach to executive compensation.

Future Outlook

This filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider equity compensation event for a director of Lucid Diagnostics Inc. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's long-term interests with shareholder value creation.
• Employees: While this specific grant is to a director, the underlying plan (2018 Long-Term Incentive Equity Plan) may also cover other employees, indicating a broader compensation strategy.

Next Steps

• The options will vest according to a schedule, with the first tranche on June 30, 2026, and subsequent quarterly installments until June 30, 2028.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation. It does not provide new material information about the company's financial performance, operational outlook, or strategic direction that would warrant a change in investment recommendation. It is a standard insider transaction aimed at aligning interests.

Keywords

Lucid Diagnostics, LUCD, stock options, insider transaction, Form 4, John R. Palumbo, equity compensation, director compensation